Monoclonal antibody Hu8H9 I-131 - Y-mAbs Therapeutics

Drug Profile

Monoclonal antibody Hu8H9 I-131 - Y-mAbs Therapeutics

Alternative Names: 131I-Hu8H9 (B7-H3)

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD antigen modulators; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Soft tissue sarcoma

Most Recent Events

  • 04 Oct 2016 Preclinical trials in Soft tissue sarcoma in USA (Parenteral)
  • 14 Oct 2014 Y-mAbs Therapeutics in-licenses anti-B7-H3 antibody programme from Memorial Sloan Kettering Cancer Center
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top